Transaction Details

Footnotes

These transactions occurred automatically pursuant to a plan adopted by the Reporting Person on August 15, 2024, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.01 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.